CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
salsalatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00258115
NCT00258115Phase 2Completed
CompareCT.gov

The Study of Inhibition of Inflammation in the Dysmetabolic Syndrome of Obesity

Joslin Diabetes Center·interventional·Posted Nov 24, 2005·Updated Feb 15, 2018

In Brief

A Phase 2 clinical trial evaluating salsalate for Obesity. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Chronic subaccute inflammation may underlie the development of diabetes cardiovascular disease and other components of the metabolic syndrome. Rodent studies suggest diet induced obesity is associated with activation of the IKK/NF-kB pathway and this pathway can be inhibited by salicylates. This study seeks to determine the effect of salicylates in overweight persons.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 24, 2005
Enrollment StartDec 1, 2003
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 20.6 years ago

Interventions

salsalatedrug